KRAS and neoplasm: Future experiments will include chronic rapamycin treatment of mice bearing the PTEN−/−, 10A-KRAS(G12V), and PTEN−/−KRAS(G12V) cells to determine if rapamycin can eliminate dormant cells and/or delay the tumor formation from the aggressive PTEN−/−KRAS(G12V) cells.